Literature DB >> 23354835

Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples.

Andrew D Watt1, Keyla A Perez, Alan Rembach, Nicki A Sherrat, Lin Wai Hung, Timothy Johanssen, Catriona A McLean, Woan Mei Kok, Craig A Hutton, Michelle Fodero-Tavoletti, Colin L Masters, Victor L Villemagne, Kevin J Barnham.   

Abstract

The formation of low-order oligomers of β-amyloid (Aβ) within the brain is widely believed to be a central component of Alzheimer's disease (AD) pathogenesis. However, despite advances in high-throughput and high-resolution techniques such as xMAP and mass spectrometry (MS), investigations into these oligomeric species have remained reliant on low-resolution Western blots and enzyme-linked immunosorbent assays. The current investigation compared Aβ profiles within human cortical tissue using sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE), xMAP and surface enhanced laser desorption/ionization time-of-flight MS and found that whilst there was significant correlation across the techniques regarding levels of monomeric Aβ, only SDS-PAGE was capable of detecting dimeric isoforms of Aβ. The addition of synthetic di-tyrosine cross-linked Aβ(1-40)Met(35)(O) to the AD tissue demonstrated that the MS methodology was capable of observing dimeric Aβ at femto-molar concentrations, with no noticeable effect on monomeric Aβ levels. Focus turned to the association between SDS-PAGE and levels of observable dimeric Aβ within the AD brain tissue. These investigations revealed that increased levels of dimeric Aβ were observed with increasing concentrations of SDS in the sample buffer. This finding was subsequently confirmed using synthetic Aβ(1-42) and suggests that SDS was inducing the formation of dimeric Aβ. The findings that SDS promotes Aβ dimerization have significant implications for the putative role of low-order oligomers in AD pathogenesis and draw into question the utility of oligomeric Aβ as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23354835     DOI: 10.1007/s00401-013-1083-z

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  35 in total

1.  The aqueous phase of Alzheimer's disease brain contains assemblies built from ∼4 and ∼7 kDa Aβ species.

Authors:  Jessica M Mc Donald; Tiernan T O'Malley; Wen Liu; Alexandra J Mably; Gunnar Brinkmalm; Erik Portelius; William M Wittbold; Matthew P Frosch; Dominic M Walsh
Journal:  Alzheimers Dement       Date:  2015-04-04       Impact factor: 21.566

2.  PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.

Authors:  David Mengel; Wei Hong; Grant T Corbett; Wen Liu; Alexandra DeSousa; Laura Solforosi; Cheng Fang; Matthew P Frosch; John Collinge; David A Harris; Dominic M Walsh
Journal:  Brain Res       Date:  2018-12-26       Impact factor: 3.252

3.  Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology.

Authors:  Shan Liu; Ariel Breitbart; Yanjie Sun; Pankaj D Mehta; Allal Boutajangout; Henrieta Scholtzova; Thomas Wisniewski
Journal:  J Neurochem       Date:  2013-11-06       Impact factor: 5.372

4.  Zinc Is Involved in Depression by Modulating G Protein-Coupled Receptor Heterodimerization.

Authors:  Mercè Tena-Campos; Eva Ramon; Cecylia S Lupala; Juan J Pérez; Karl-W Koch; Pere Garriga
Journal:  Mol Neurobiol       Date:  2015-04-09       Impact factor: 5.590

Review 5.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

6.  Spectroscopic Signature for Stable β-Amyloid Fibrils versus β-Sheet-Rich Oligomers.

Authors:  Justin P Lomont; Kacie L Rich; Michał Maj; Jia-Jung Ho; Joshua S Ostrander; Martin T Zanni
Journal:  J Phys Chem B       Date:  2017-12-27       Impact factor: 2.991

7.  Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer's brain.

Authors:  Gunnar Brinkmalm; Wei Hong; Zemin Wang; Wen Liu; Tiernan T O'Malley; Xin Sun; Matthew P Frosch; Dennis J Selkoe; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Dominic M Walsh
Journal:  Brain       Date:  2019-05-01       Impact factor: 13.501

8.  Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.

Authors:  Beatriz G Perez-Nievas; Thor D Stein; Hwan-Ching Tai; Oriol Dols-Icardo; Thomas C Scotton; Isabel Barroeta-Espar; Leticia Fernandez-Carballo; Estibaliz Lopez de Munain; Jesus Perez; Marta Marquie; Alberto Serrano-Pozo; Mathew P Frosch; Val Lowe; Joseph E Parisi; Ronald C Petersen; Milos D Ikonomovic; Oscar L López; William Klunk; Bradley T Hyman; Teresa Gómez-Isla
Journal:  Brain       Date:  2013-07-03       Impact factor: 13.501

Review 9.  Amyloid β oligomers (AβOs) in Alzheimer's disease.

Authors:  Barbara Mroczko; Magdalena Groblewska; Ala Litman-Zawadzka; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2017-12-01       Impact factor: 3.575

10.  Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease.

Authors:  Rebecca F Rosen; Yasushi Tomidokoro; Aaron S Farberg; Jeromy Dooyema; Brian Ciliax; Todd M Preuss; Thomas A Neubert; Jorge A Ghiso; Harry LeVine; Lary C Walker
Journal:  Neurobiol Aging       Date:  2016-05-02       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.